RYTM — Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 2025 Revenue: $57.3 million, a 12% increase from Q3 2025 and a 37% increase year-over-year.
• Full Year 2025 Revenue: $194.8 million, representing approximately a 50% increase from 2024.
• U.S. Revenue: $39 million (68% of total), with $18.3 million (32%) generated internationally.
• Gross to Net for U.S. Sales: Approximately 84.6%.
• Cost of Goods Sold (COGS): 8.5% of product revenue.
• R&D Expenses: $42 million for Q4, slightly up from $41.2 million year-over-year.
• SG&A Expenses: $57.5 million for Q4, up from $38.1 million in Q4 2024, driven by increased headcount and professional fees.
• Net Loss per Share: $0.73 for Q4, with cash used in operations around $25 million.
• Cash Position: Approximately $389 million at year-end, sufficient to fund operations for at least 24 months.

2. Strategic Updates and Business Highlights:

• Bivamelagon Development: Positive FDA end-of-phase 2 meeting, with plans to initiate phase 3 trials by year-end 2026. The trial will require a 12-month double-blind study with a larger patient cohort.
• Acquired Hypothalamic Obesity (HO): Preparations for launch pending regulatory approval, with a PDUFA date set for March 20, 2026. The company has expanded its sales force to 42 members to support the launch.
• International Growth: IMCIVREE is now available in over 25 countries, with significant growth driven by early access programs in France and Italy.
• Patient Engagement: Ongoing efforts to educate healthcare providers about Acquired HO and secure reimbursement for IMCIVREE.

3. Forward Guidance and Outlook:

• 2026 Non-GAAP Operating Expenses: Expected to be between $385 million and $415 million, reflecting a 35% increase year-over-year, driven by R&D and commercial operations for HO.
• Upcoming Milestones: Anticipated top-line data from the Japanese HO cohort and M&A readout by the end of March 2026.

4. Bad News, Challenges, or Points of Concern:

• Inventory Management: Increased days on hand at specialty pharmacies, indicating potential revenue pull-forward from Q4 to Q1 2026, which could dampen Q1 sales.
• Regulatory Requirements: The FDA's insistence on a full 12-month phase 3 trial for bivamelagon may delay timelines and increase costs.
• Market Competition: The presence of other obesity treatments, including setmelanotide, may impact the adoption of IMCIVREE for Acquired HO.

5. Notable Q&A Insights:

• Bivamelagon Phase 3 Trial: The trial will likely mirror the setmelanotide phase 3 design, focusing on a target dose of 600 mg.
• Patient Identification for HO: The company is actively identifying more patients diagnosed with or suspected to have Acquired HO, with numbers increasing from previous estimates.
• Regulatory Strategy: Each genetic mutation will likely require separate sNDA filings, although future regulatory pathways may evolve.
• Market Access in Japan: The company is building its presence in Japan, anticipating a launch within 12 months post-data submission.

Overall, Rhythm Pharmaceuticals is positioned for growth with strong revenue performance and strategic initiatives aimed at expanding its market presence, despite facing regulatory and competitive challenges.